Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Curevo has raised $110.0M in total funding. The most recent round was Series B. The last funding was announced in March 2025.
Curevo's investors include RA Capital Management, Janus Henderson Investors, OrbiMed, Sanofi Ventures, Medicxi.
Curevo is headquartered in Bothell, United States.
Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.
Curevo is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Curevo — Funding & Investors." VCBacked, March 17, 2025, https://www.vcbacked.co/company/curevo. Accessed July 31, 2026.
VCBacked. (2025). Curevo — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/curevo
{{cite web |title=Curevo — Funding & Investors |url=https://www.vcbacked.co/company/curevo |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated